Investigating how exercise affects insulin sensitivity through mTOR
Mechanistic Target of Rapamycin (mTOR) as Mediator of Exercise-induced Insulin Sensitivity Study
This study is testing if a medication that blocks a specific pathway in the body can change how exercise helps young healthy men improve their insulin sensitivity.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 22 Years to 35 Years |
| Sex | Male |
| Sponsor | University of Copenhagen Academic / other |
| Locations | 1 site (Copenhagen) |
| Trial ID | NCT05233722 on ClinicalTrials.gov |
What this trial studies
This study examines the role of the mTOR pathway in enhancing muscle insulin sensitivity after exercise in young healthy males. Participants will undergo a controlled exercise regimen while receiving either a pharmacological mTOR inhibitor, Rapamycin, or a placebo. The study employs a crossover design, allowing each participant to serve as their own control, with various blood sampling and infusion protocols to measure muscle glucose uptake and protein synthesis. The goal is to understand the biochemical mechanisms that improve insulin sensitivity through exercise.
Who should consider this trial
Good fit: Ideal candidates are healthy young men aged 22-35 with a BMI between 18.0 and 25.0 who engage in moderate physical activity.
Not a fit: Patients who are women, highly active individuals, or those with metabolic diseases will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new strategies for improving insulin sensitivity, which is crucial for preventing metabolic diseases.
How similar studies have performed: While the specific approach of using mTOR inhibition in this context is novel, related studies have shown promising results in understanding the role of exercise in insulin sensitivity.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Healthy persons (no known disease) without diabetes in the family * No use of medications * Non-smokers * Men * Age 22-35 years * Physical activity level (VO2peak) between 30-50 mL O2/min/kg * BMI between 18.0 and 25.0 Exclusion Criteria: * Women * Physical activity (e.g., running, cycling, fitness, etc.) above 6 hours a week. * Persons who show signs of metabolic diseases, hematologic diseases, reduced liver function, human immunodeficiency virus (HIV), hepatitis, thyroid diseases or other signs of disease that may affect the outcome of the study or the study subject's wellbeing will be excluded. * Acute sickness less than 2 weeks prior to study start. * If disease appears or is identified and/or a need for medication arises after inclusion but before initiation of the study. Disease during conclusion of the study
Where this trial is running
Copenhagen
- University of Copenhagen — Copenhagen, Denmark (Recruiting)
Study contacts
- Principal investigator: Jørgen FP Wojtaszewski, Professor — Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Denmark
- Study coordinator: Jørgen FP Wojtaszewski, Professor
- Email: jw@nexs.ku.dk
- Phone: +4535321625
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.